A crop-protection company reports revenue down 7% and EBITDA margin down 320 basis points to 14.1% after a monsoon 22% below the long-period average. Channel inventory is 71 days against a normal 45. Receivables are 118 days against 82. The company has launched four new molecules in two years, which are 18% of revenue at gross margins 900 basis points above the portfolio average. The stock is down 34% from its high and trades at 21x trailing earnings against a five-year median of 29x.
Write a note with rating, target and thesis in the opening, the derivation, the two or three drivers, and what would break the call.
100 points, 60% to pass.
The temptation is to call a cyclical bottom on a de-rated multiple. The figures that should give pause are the working-capital ones: 71 days of channel inventory and 118 days of receivables mean the reported revenue has been pushed into a channel that has not sold it, so next season's revenue is already partly spent. Trailing earnings are therefore the wrong denominator for the multiple. The genuine positive is the new molecules at 18% of revenue and materially higher gross margin, which is a mix story independent of the monsoon. A strong note prices the normalisation of working capital explicitly and names the next monsoon forecast as the obvious falsifier.